A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

Sunil K. Joshi; Setareh Sharzehi; Janét Pittsenbarger; Daniel Bottomly; Cristina E. Tognon; Shannon K. McWeeney; Brian J. Druker; Elie Traer

doi:10.1002/ajh.26174

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

Sunil K. Joshi, Setareh Sharzehi, Janét Pittsenbarger, Daniel Bottomly, Cristina E. Tognon, Shannon K. McWeeney, Brian J. Druker, Elie Traer

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	E226-E229
Journal	American Journal of Hematology
Volume	96
Issue number	7
DOIs	https://doi.org/10.1002/ajh.26174
State	Published - Jul 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26174

Cite this

@article{33beeb0925594b969afea0a8eb36bac8,

title = "A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance",

author = "Joshi, {Sunil K.} and Setareh Sharzehi and Jan{\'e}t Pittsenbarger and Daniel Bottomly and Tognon, {Cristina E.} and McWeeney, {Shannon K.} and Druker, {Brian J.} and Elie Traer",

note = "Funding Information: We are extremely thankful to the Massively Parallel Sequencing Shared Resource for technical support. We thank Sudarshan Iyer for assistance with UCSF Chimera. This work was supported by the American Cancer Society (MRSG‐17‐040‐01‐LIB) to E.T., the Drug Sensitivity and Resistance Network (DRSN; U54CA224019) to B.J.D, S.K.M, and E.T, and Cancer Center Support grant (5P30CA069533‐22) to B.J.D. Additional funding was provided by the Howard Hughes Medical Institute, and The Leukemia & Lymphoma Society to E.T. and B.J.D. S.K.J. is supported by the ARCS Scholar Foundation, The Paul & Daisy Soros Fellowship, and the National Cancer Institute (F30CA239335). E.T. is supported by grants from the Leukemia & Lymphoma Society, Hildegard Lamfrom Physician Scientist Award, American Cancer Society, and Cancer Early Detection Advanced Research Center. C.T., D.B., S.K.M., B.J.D, and E.T. were all supported by National Cancer Institute (U54CA224019). ",

year = "2021",

month = jul,

day = "1",

doi = "10.1002/ajh.26174",

language = "English (US)",

volume = "96",

pages = "E226--E229",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

AU - Joshi, Sunil K.

AU - Sharzehi, Setareh

AU - Pittsenbarger, Janét

AU - Bottomly, Daniel

AU - Tognon, Cristina E.

AU - McWeeney, Shannon K.

AU - Druker, Brian J.

AU - Traer, Elie

N1 - Funding Information: We are extremely thankful to the Massively Parallel Sequencing Shared Resource for technical support. We thank Sudarshan Iyer for assistance with UCSF Chimera. This work was supported by the American Cancer Society (MRSG‐17‐040‐01‐LIB) to E.T., the Drug Sensitivity and Resistance Network (DRSN; U54CA224019) to B.J.D, S.K.M, and E.T, and Cancer Center Support grant (5P30CA069533‐22) to B.J.D. Additional funding was provided by the Howard Hughes Medical Institute, and The Leukemia & Lymphoma Society to E.T. and B.J.D. S.K.J. is supported by the ARCS Scholar Foundation, The Paul & Daisy Soros Fellowship, and the National Cancer Institute (F30CA239335). E.T. is supported by grants from the Leukemia & Lymphoma Society, Hildegard Lamfrom Physician Scientist Award, American Cancer Society, and Cancer Early Detection Advanced Research Center. C.T., D.B., S.K.M., B.J.D, and E.T. were all supported by National Cancer Institute (U54CA224019).

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85104157954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104157954&partnerID=8YFLogxK

U2 - 10.1002/ajh.26174

DO - 10.1002/ajh.26174

M3 - Letter

C2 - 33780043

AN - SCOPUS:85104157954

SN - 0361-8609

VL - 96

SP - E226-E229

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 7

ER -

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this